Skip to main content

previous disabled Page of 2
and
  1. No Access

    Article

    The why, when, where, how, and so what of so-called rapidly acting antidepressants

    Develo** antidepressants that are not only more effective but are rapidly acting is the Holy Grail for psychiatry. We review multiple issues that arise in determining rapid responses in antidepressant trials...

    Alan F. Schatzberg, Sanjay J. Mathew in Neuropsychopharmacology (2024)

  2. Article

    Open Access

    Neurotransmission-related gene expression in the frontal pole is altered in subjects with bipolar disorder and schizophrenia

    The frontal pole (Brodmann area 10, BA10) is the largest cytoarchitectonic region of the human cortex, performing complex integrative functions. BA10 undergoes intensive adolescent grey matter pruning prior to...

    Adriana M. Medina, Megan Hastings Hagenauer, David M. Krolewski in Translational Psychiatry (2023)

  3. Article

    Open Access

    Mitochondria DNA copy number, mitochondria DNA total somatic deletions, Complex I activity, synapse number, and synaptic mitochondria number are altered in schizophrenia and bipolar disorder

    Mitochondrial dysfunction is a neurobiological phenomenon implicated in the pathophysiology of schizophrenia and bipolar disorder that can synergistically affect synaptic neurotransmission. We hypothesized tha...

    Sujan C. Das, Brooke E. Hjelm, Brandi L. Rollins in Translational Psychiatry (2022)

  4. Article

    Open Access

    Identification of potential blood biomarkers associated with suicide in major depressive disorder

    Suicides have increased to over 48,000 deaths yearly in the United States. Major depressive disorder (MDD) is the most common diagnosis among suicides, and identifying those at the highest risk for suicide is ...

    Firoza Mamdani, Matthieu D. Weber, Blynn Bunney, Kathleen Burke in Translational Psychiatry (2022)

  5. Article

    Open Access

    A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials

    Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD) as subtypes of major depressive disorder (MDD) are not unequivocally defined. In the present document we used a Delph...

    Luca Sforzini, Courtney Worrell, Melisa Kose, Ian M. Anderson in Molecular Psychiatry (2022)

  6. Article

    Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al.

    Boris D. Heifets, Brandon S. Bentzley, Nolan Williams in Molecular Psychiatry (2021)

  7. Article

    Open Access

    Decoding the temporal nature of brain GR activity in the NFκB signal transition leading to depressive-like behavior

    The fine-tuning of neuroinflammation is crucial for brain homeostasis as well as its immune response. The transcription factor, nuclear factor-κ-B (NFκB) is a key inflammatory player that is antagonized via an...

    Young-Min Han, Min Sun Kim, Juyeong Jo, Daiha Shin, Seung-Hae Kwon in Molecular Psychiatry (2021)

  8. No Access

    Article

    Long-term effects of intermittent early life stress on primate prefrontal–subcortical functional connectivity

    Correlational studies of humans suggest that exposure to early life stress has long-term effects on neural circuits involved in vulnerability and resilience to mental health disorders. Stress-related mental he...

    Rui Yuan, Jordan M. Nechvatal, Christine L. Buckmaster in Neuropsychopharmacology (2021)

  9. No Access

    Article

    Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial

    There is a critical need to better understand the neural basis of antidepressant medication (ADM) response with respect to both symptom alleviation and quality of life (QoL) in major depressive disorder (MDD)....

    Adina S. Fischer, Bailey Holt-Gosselin, Scott L. Fleming in Neuropsychopharmacology (2021)

  10. Article

    Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

    Supplementary Figure 1 and Supplementary Tables 1–4 have been re-uploaded so as to reflect the versions supplied during proofs stage. The publisher apologizes for the error in versioning. The HTML version of t...

    Maurizio Fava, Marlene P. Freeman, Martina Flynn, Heidi Judge in Molecular Psychiatry (2020)

  11. Article

    Open Access

    Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

    Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA receptor antagonist, to induce rapid (within hours), transient antidepressant effects when administered intravenously (IV)...

    Maurizio Fava, Marlene P. Freeman, Martina Flynn, Heidi Judge in Molecular Psychiatry (2020)

  12. Article

    In Memoriam of George Gardos, MD

    Alan F. Schatzberg in Neuropsychopharmacology (2020)

  13. No Access

    Article

    Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism

    We recently reported that naltrexone blocks antidepressant effects of ketamine in humans, indicating that antidepressant effects of ketamine require opioid receptor activation. However, it is unknown if opioid...

    Nolan R. Williams, Boris D. Heifets, Brandon S. Bentzley in Molecular Psychiatry (2019)

  14. Article

    Open Access

    Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study

    Due to lacking predictors of depression recovery, successful treatment of major depressive disorder (MDD) is frequently only achieved after therapeutic optimization leading to a prolonged suffering of patients...

    Bernhard M. Meyer, Ulrich Rabl, Julia Huemer, Lucie Bartova in Translational Psychiatry (2019)

  15. No Access

    Article

    Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates

    Recent evidence highlights the fibroblast growth factor (FGF) family in emotion modulation. Although ligands that activate FGF receptors have antidepressant and anxiolytic effects in animal models, FGF ligands...

    Cortney A. Turner, David M. Lyons, Christine L. Buckmaster in Neuropsychopharmacology (2019)

  16. Article

    Open Access

    Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression

    Corticotropin-releasing factor signaling through CRF receptor type 1 (CRF1) has been shown to contribute to learning and memory function. A haplotype of alleles T-A-T in a set of common polymorphisms in the gene ...

    Elena Goetz Davis, Jennifer Keller, Joachim Hallmayer in Translational Psychiatry (2018)

  17. Article

    Eberhard H Uhlenhuth

    Alan F Schatzberg, Samuel J Keith in Neuropsychopharmacology (2016)

  18. Article

    A Cognitive–Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D Trial

    Depression involves impairments in a range of cognitive and emotional capacities. It is unknown whether these functions can inform medication choice when considered as a composite predictive biomarker. We test...

    Amit Etkin, Brian Patenaude, Yun Ju C Song, Timothy Usherwood in Neuropsychopharmacology (2015)

  19. Article

    Erratum: Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

    Correction to: Neuropsychopharmacology (2015) 40, 259–267; doi:10.1038/npp.2014.261; published online 22 October 2014 On page 262 (first paragraph under ‘Ketamine’s Abuse Liability: Mu Opioid Receptor Effects’...

    Gerard Sanacora, Alan F Schatzberg in Neuropsychopharmacology (2015)

  20. Article

    Decreased Hypothalamic Functional Connectivity with Subgenual Cortex in Psychotic Major Depression

    Hypothalamus communication with the rest of the brain and peripheral target tissues is critically important for many physiological and psychological functions. These functions include maintaining neuroendocrin...

    Keith Sudheimer, Jennifer Keller, Rowena Gomez in Neuropsychopharmacology (2015)

previous disabled Page of 2